Our findings align with previous studies demonstrating that PARG depletion enhances the efficacy of chemotherapeutic agents in melanoma, ovarian cancer, glioblastoma, and head and neck cancer.43, 44, 45, 46. This evidence concerns the gene PARG and glioblastoma.